Live Breaking News & Updates on Paragon biosciences

Stay informed with the latest breaking news from Paragon biosciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Paragon biosciences and stay connected to the pulse of your community

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , United-states , Americans , Luis-sanay , Jeffreym-dayno , Epygenix-company-presentation , European-medicines-agency , Epygenix-therapeutics-inc , Nasdaq , Exchange-commission , European-union , Share-repurchase-program

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its ...

WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year

United-kingdom , United-states , Americans , Luis-sanay , Jeffreym-dayno , Epygenix-therapeutics-inc , Exchange-commission , Epygenix-company-presentation , Share-repurchase-program , European-union , European-medicines-agency , Harmony-biosciences-holdings-inc

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and...

France , Paris , France-general- , United-states , French , American , Luis-sanay , Pitolisant-wakix , Jean-charles-schwartz , Jeffreym-dayno , Prnewswire-harmony-biosciences-holdings-inc , Exchange-commission

Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist

Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Paris , France-general- , France , United-states , American , French , Jeffreym-dayno , Luis-sanay , Pitolisant-wakix , Dennis-riedl , Jean-charles-schwartz , Drug-administration

A2 Bio's new CEO aims to grow platform | Pacific Coast Business Times

A2 Bio's new CEO aims to grow platform | Pacific Coast Business Times
pacbiztimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pacbiztimes.com Daily Mail and Mail on Sunday newspapers.

David-goeddel , Alexander-kamb , Scott-foraker , James-robinson , Sumitovant-biopharma , Sumitomo-pharma-america-inc , Alkermes , Amgen , Urovant-sciences , Mike-harris-monday , Business-times

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to...

United-states , France , Luis-sanay , Kumar-budur , Exchange-commission , Zynerba-pharmaceuticals , Prnewswire-harmony-biosciences-holdings-inc , Drug-administration , Paragon-biosciences , Us-food-drug-administration , Biosciences-holdings , Orphan-drug-designation

HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the...

Luis-sanay , Prnewswire-harmony-biosciences-holdings-inc , Paragon-biosciences , Nasdaq , Biosciences-holdings , Annual-needham-virtual-healthcare-conference , Harmony-biosciences , Plymouth-meeting , Biosciences-investor-contact , Biosciences-media-contact ,

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming...

Miami , Florida , United-states , Luis-sanay , Paragon-biosciences , Nasdaq , Harmony-biosciences-holdings-inc , Barclays , Harmony-biosciences-holdings , Partners-global-biopharma-conference , Annual-global-healthcare , Harmony-biosciences

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

WAKIX® Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration Granted...

United-states , United-kingdom , Americans , Luis-sanay , Jeffreym-dayno , Idiopathic-hypersomnia-development-program-scheduled-for , Paragon-biosciences , European-medicines-agency , Drug-administration , Nasdaq , European-union , Zynerba-pharmaceuticals

U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) granted priority review for its...

France , United-states , Americans , Luis-sanay , Jeffreym-dayno , Drug-administration , Paragon-biosciences , Nasdaq , Prnewswire-harmony-biosciences-holdings-inc , Exchange-commission , Prescription-drug-user-fee-act , Biosciences-holdings